Financial Contrast: SOPHiA GENETICS (NASDAQ:SOPH) and Bullfrog AI (NASDAQ:BFRG)

SOPHiA GENETICS (NASDAQ:SOPHGet Free Report) and Bullfrog AI (NASDAQ:BFRGGet Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Volatility & Risk

SOPHiA GENETICS has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of -2.89, suggesting that its stock price is 389% less volatile than the S&P 500.

Institutional and Insider Ownership

31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 25.2% of Bullfrog AI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares SOPHiA GENETICS and Bullfrog AI’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SOPHiA GENETICS -44.48% -62.74% -21.85%
Bullfrog AI N/A -217.80% -174.57%

Analyst Ratings

This is a summary of current recommendations for SOPHiA GENETICS and Bullfrog AI, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SOPHiA GENETICS 1 0 2 0 2.33
Bullfrog AI 1 0 0 0 1.00

SOPHiA GENETICS currently has a consensus target price of $7.50, suggesting a potential upside of 42.05%. Given SOPHiA GENETICS’s stronger consensus rating and higher probable upside, analysts clearly believe SOPHiA GENETICS is more favorable than Bullfrog AI.

Earnings and Valuation

This table compares SOPHiA GENETICS and Bullfrog AI”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SOPHiA GENETICS $81.18 million 4.45 -$79.00 million ($0.52) -10.15
Bullfrog AI $120,000.00 103.61 -$6.50 million ($0.54) -1.24

Bullfrog AI has lower revenue, but higher earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Summary

SOPHiA GENETICS beats Bullfrog AI on 9 of the 14 factors compared between the two stocks.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

About Bullfrog AI

(Get Free Report)

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.